Strategic Oncology Focus Synta is an agile biopharma specializing in novel oncology medicines with a lead Hsp90 inhibitor ganetespib and a Drug Conjugate Program, presenting multiple near-term collaboration and licensing opportunities in cancer indications.

Clinical Progress Levers Ganetespib is in several large randomized trials including a pivotal phase 3 in NSCLC and other cancers, signaling substantial late-stage development potential for partnered development, co-commercialization, or milestone-based collaboration.

HDC Expansion Potential The proprietary Hsp90 inhibitor Drug Conjugate Program, with STA-12-8666 advancing toward IND, offers opportunities to license or co-develop targeted payloads, expanding a partner’s oncology portfolio and patient stratification capabilities.

Financial Readiness With a revenue range of 25-50 million and significant external funding (217 million), Synta demonstrates financing capacity to support collaborative research, milestone payments, and joint development initiatives.

SME Collaboration Fit As a smaller, innovative player with substantial trial activity and a focused team, Synta is an attractive partner for pharma and biotech seeking nimble collaboration, rapid due diligence, and co-development pathways in oncology.